COMMENTARIES

The Importance of Gas6/Axl Anti-Apoptotic Signaling in Regulating Vascular Calcification

Andrew Sage and Ann Canfield, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, U.K., Email: ann.canfield@manchester.ac.uk

Introduction

Vascular calcification refers to the aberrant development of cartilage and bone-like tissue and associated mineralization of the extracellular matrix at distinct locations within the vascular system: atherosclerotic plaques, the medial layer of large and medium-sized arteries, and cardiac valves.

Calcification is a common and significant component of atherosclerotic plaques, with estimates of its occurrence ranging from 60-90% [1,2]. While vascular calcification has been recognized and described by pathologists for more than a century (reviewed in [3]), until recently it was regarded as a consequence of the aging and deterioration of the vascular system in the elderly [4]. Now, however, the prevalence and clinical importance of vascular calcification in younger people with major chronic systemic diseases including cardiovascular disease, diabetes, and chronic kidney disease is more widely recognized [2]. Vascular calcification is not only highly prevalent and progressive in these diseases, but there is now substantial evidence that calcification directly contributes to the morbidity and mortality associated with these common and serious conditions [1,2,4]. This concept has led to a greatly increased interest in vascular calcification in terms of molecular research, clinical studies as well as the modification of current treatment regimes.

It is now established that vascular calcification is an active, cell-mediated process that resembles embryonic bone development [1,5-7]. At the molecular level, the causes and inducing factors involved in the initiation and early progression of vascular calcification are complex and still not fully understood. Altered metabolic homeostasis, such as hyperlipidemia or hyperphosphatemia, inflammation, and associated oxidative stress may be considered important underlying conditions that promote vascular calcification in addition to other cardiovascular complications. These conditions lead to both the active promotion of bone formation through a variety of pathways, as well as the loss or dysfunction of inhibitory mechanisms that normally act to prevent calcification outside the skeleton [4,5]. For example, increased TNF-α promotes vascular calcification [8] whereas reduced fetuin-A promotes calcification [9].

 

The Role of Apoptosis in Vascular Calcification

Apoptosis is an inbuilt program for cell death which is carried out by the caspase family of proteases. Current evidence suggests that this process is required for vascular calcification. For example, apoptosis is co-localized with both medial and atherosclerotic calcification in humans [10,11]. Furthermore, mineral deposition by vascular smooth muscle cells (VSMC) and pericytes is associated with increased apoptosis, and incubation of these cells with the caspase inhibitor zVADfmk inhibits mineral deposition [12-14 and unpublished data]. A recent paper also demonstrated that inducing chronic low-grade apoptosis in VSMCs of ApoE-/- mice induces atherosclerotic calcification in vivo [15]

It is possible that vascular osteoprogenitor cells undergo a matrix vesicle and/or apoptotic body-mediated process of mineralization similar to that described for hypertrophic chondrocytes [16,17]. Persuasive evidence indicates that chondrocyte apoptosis is an integral part of the differentiation pathway of these cells and is the terminal (and inevitable) phase of the transition to the hypertrophic stage, when mineralization first begins [16,17]. Both in vivo and in vitro, terminal differentiation of chondrocytes are associated with a decrease in the anti-apoptotic protein Bcl-2 and an increase in the pro-apoptotic proteins Bax and caspase-3 [16-18]. These changes are detectable before morphological evidence of apoptosis, suggesting that hypertrophic chondrocytes are primed for apoptosis but are held in a pre-apoptotic state until induced by, for example, factors introduced during vascular invasion [16-18]. In further support of this hypothesis, increased Pi selectively induces apoptosis of terminally-differentiated but not undifferentiated chondrocytes in vitro [17,18]. Therefore, determining whether a similar sensitization to apoptosis is responsible for vascular osteoprogenitor mineralization is an important goal for future studies.

 

Gas6 – Axl Survival Signaling Inhibits Vascular Calcification

The receptor tyrosine kinase Axl is activated by the vitamin K-dependent GLA protein, growth arrest specific-6 (Gas6). Axl has emerged as a critical regulator of vascular wall homeostasis, particularly in situations of acute and chronic injury [19] and of apoptosis [20]. Furthermore, in vitro studies from our lab and others have demonstrated that Axl and Gas6 may play an important role in vascular calcification. Axl was first identified as a regulator of mineralization in microvascular pericytes that spontaneously undergo osteogenic differentiation and form mineralized nodules [21,22]. Axl is specifically down-regulated in mineralized pericyte nodules, and inhibition of Axl activation with a decoy Axl receptor (Axl-ECD) accelerated mineralization, indicating the loss of Axl expression may be functionally significant [21].

More recent work from our lab and others has demonstrated that Axl down-regulation also occurs in mineralized human and bovine aortic VSMCs [12,23]. To determine the function of Axl in VSMCs, we modulated Axl expression using recombinant adenoviruses encoding either wild-type or kinase-dead mutant Axl (KD-Axl). Wild-type Axl over-expression significantly inhibited calcification; in contrast, over-expression of KD-Axl significantly accelerated calcification, implicating active signaling as the inhibitory entity. Consistent with other reports [20], we demonstrated that Axl increases PI3K-Akt signaling in these cells and furthermore that signaling via this pathway is critical for the effects of Axl on calcification [12 and unpublished data]. Additional experiments from our lab and recent work by Son et al. have also determined that Axl-PI3K signaling regulates calcification by preventing apoptosis, which would otherwise promote matrix vesicle/apoptotic body-mediated mineral formation in these cells [23]  (see above). We also demonstrated that the increased calcification induced by KD-Axl was abrogated in the presence of zVAD.fmk, indicating that KD-Axl stimulates calcification by promoting apoptosis [12].

The loss of Axl expression may, therefore, be one mechanism by which mineralizing VSMCs become sensitized to apoptosis, allowing the completion of the mineralization process. Interestingly, Gas6-Axl survival signaling has also been identified as a downstream target of both phosphate and TNF-α [24], known inducers of calcification in vivo and in vitro [8,25]. Like many regulatory molecules, Axl is likely to have temporal and cell-specific roles in atherosclerosis [19], and as such, may not be a candidate for direct intervention to prevent calcification. However, our studies highlight its potentially important role in this process and lend further support to the hypothesis that apoptosis is involved in vascular calcification.

References

  1.    Abedin M, Tintut Y, Demer LL. 2004. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24: 1161-70.
  2.    Budoff MJ, Shaw LJ, Liu ST, et al. 2007. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 49: 1860-70.
  3.    Qunibi WY, Nolan CA, Ayus JC. 2002. Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int Suppl: 73-80.
  4.    Doherty TM, Fitzpatrick LA, Inoue D, et al. 2004. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25: 629-72.
  5.    Johnson RC, Leopold JA, Loscalzo J. 2006. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99: 1044-59.
  6.    Collett GD, Canfield AE. 2005. Angiogenesis and pericytes in the initiation of ecotopic calcification. Circ Res 96: 930-38.
  7.    Demer LL, Tintut Y. 2008. Vascular calcification: Pathobiology of a multifaceted disease. Circulation 117: 2938-48.
  8.    Al-Aly Z, Shao JS, Lai CF, et al. 2007. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 27: 2589-96.
  9.    Ketteler M, Bongartz P, Westenfeld R, et al. 2003. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361: 827-33.
  10.    Schoppet M, Al-Fakhri N, Franke FE, et al. 2004. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89: 4104-12.
  11.    Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. 1998. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 97: 2307-15.
  12.    Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. 2007. Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res 100: 502-9.
  13.    Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. 2000. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87: 1055-62.
  14.    Son BK, Kozaki K, Iijima K, et al. 2006. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 98; 1024-31.
  15.    Clarke MC, Littlewood TD, Figg N, et al. 2008. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res In press. Published online ahead of print doi: 10.1161/ CIRCRESAHA.108.175976
  16.    Gibson G. 1998. Active role of chondrocyte apoptosis in endochondral ossification. Microsc Res Tech 43: 191-204.
  17.    Magne D, Bluteau G, Faucheux C, et al. 2003. Phosphate is a specific signal for ATDC5 chondrocyte maturation and apoptosis-associated mineralization: possible implication of apoptosis in the regulation of endochondral ossification. J Bone Miner Res 18: 1430-42.
  18.    Pucci B, Adams CS, Fertala J, et al. 2007. Development of the terminally differentiated state sensitizes epiphyseal chondrocytes to apoptosis through caspase-3 activation. J Cell Physiol 210: 609-15.
  19.    Korshunov VA, Mohan AM, Georger MA, Berk BC. 2006. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res 98: 1446-52.
  20.    Melaragno MG, Cavet ME, Yan C, et al. 2004. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. J Mol Cell Cardiol 37: 1-7.
  21.    Collett G, Wood A, Alexander MY, et al. 2003. Receptor tyrosine kinase Axl modulates the osteogenic differentiation of pericytes. Circ Res 92: 1123-29.
  22.    Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. 1998. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res 13: 828-38.
  23.    Son BK, Kozaki K, Iijima K, et al. 2007. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 556: 1-8.
  24.    Li X, Yang HY, Giachelli CM. 2006. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905-12.
  25.    Son BK, Akishita M, Iijima K, et al. (2008). Adiponectin antagonizes stimulatory effect of tumor necrosis factor-? on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5'-monophosphate-activated protein kinase. Endocrinology 149: 1646-53.

 

 

CLOSE THE WINDOW